Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. May 28, 2005; 11(20): 3027-3033
Published online May 28, 2005. doi: 10.3748/wjg.v11.i20.3027
Published online May 28, 2005. doi: 10.3748/wjg.v11.i20.3027
Table 1 Clinical data of patients in resection group.
Item | Group A (n = 15) | Group B (n = 15) |
Sex (m/f) | 14 /1 | 14 /1 |
Age (yr) | 54.7±14.3 | 48.2±8.4 |
Mean diameter (cm) | 3.2±1.0 | 2.9±1.1 |
Child-pugh grade | A | A |
Serum AFP (mg/L) | 180±200 | 120±200 |
ALT (U/L) | 58.0±54.1 | 64.9±56.6 |
AST (U/L) | 49.9±46.8 | 42.0±37.7 |
HBsAg positive rate | 87% (13/15) | 100 (15/15) |
Table 2 Clinical data of patients in PMCT group.
Item | Group A (n = 25) | Group B (n = 16) |
Sex (m/f) | 21/4 | 15/1 |
Age (yr) | 55.8±13.4 | 57.2±11.2 |
Mean diameter (cm) | 3.5±1.0 | 3.0±0.8 |
Child-pugh grade | A | A |
Serum AFP (mg/L) | 160±200 | 120±160 |
ALT (U/L) | 52.0±42.5 | 48.1±40.1 |
AST (U/L) | 51.9±38.9 | 41.2±36.5 |
HBsAg positive rate | 76% (16/21) | 95 (20/21) |
Table 3 Expressing intensity of detected molecules in cancer tissue in groups A and B.
Table 4 Expressing intensity of 11 detected molecules in para-cancer tissue in groups A and B.
Molecule | Group A | Group B |
AFP | 0.09±0.35 | 0.00±0.00 |
c-erbB-2 | 0.76±2.50 | 0.01±0.04 |
c-met | 0.00±0.00 | 0.00±0.00 |
c-myc | 0.00±0.00 | 0.26±1.00 |
HbsAg | 9.02±5.83 | 9.11±6.19 |
HCV | 1.32±2.88 | 0.08±0.20 |
Ki-67 | 0.57±2.22 | 0.01±0.04 |
MMP-2 | 0.80±3.10 | 0.00±0.00 |
Nm23-H1 | 0.33±0.81 | 0.00±0.00 |
P53 | 0.00±0.00 | 0.00±0.00 |
VEGF | 0.04±0.15 | 0.00±0.00 |
Table 5 Variables in the regression equation.
B | SE | Wald | df | Sig | Exp (B) | 95.0% CI for EXP (B) | |||
Lower | Upper | ||||||||
Step 1 | MYCC | –0.357 | 0.213 | 2.807 | 1 | 0.094 | 0.700 | 0.461 | 1.063 |
KI-67C | –2.118 | 1.251 | 2.865 | 1 | 0.091 | 0.120 | 0.010 | 1.397 | |
MMP-2C | –0.244 | 0.306 | 0.638 | 1 | 0.425 | 0.783 | 0.430 | 1.426 | |
VEGFC | –0.367 | 0.160 | 5.269 | 1 | 0.022 | 0.693 | 0.506 | 0.948 | |
Constant | 3.680 | 1.363 | 7.289 | 1 | 0.007 | 39.64 | |||
Step 2 | MYCC | –0.412 | 0.211 | 3.795 | 1 | 0.051 | 0.663 | 0.438 | 1.003 |
KI-67C | –2.187 | 1.271 | 2.959 | 1 | 0.085 | 0.112 | 0.009 | 1.356 | |
VEGFC | –0.397 | 0.159 | 6.222 | 1 | 0.013 | 0.672 | 0.492 | 0.918 | |
Constant | 3.663 | 1.410 | 6.750 | 1 | 0.009 | 38.991 |
Table 6 Expressing intensity of detected molecules in cancer tissue in groups A and B.
Table 7 Expressing intensity of detected molecules in para-cancer tissue in groups A and B.
Molecule | Group A | Group B |
c-myc | 2.20±3.91 | 0.95±1.84 |
Ki-67 | 6.40×103±3.20×102 | 0.00±0.00 |
VEGF | 0.66±1.84 | 0.54±2.16 |
- Citation: Cui J, Dong BW, Liang P, Yu XL, Yu DJ. Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma. World J Gastroenterol 2005; 11(20): 3027-3033
- URL: https://www.wjgnet.com/1007-9327/full/v11/i20/3027.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i20.3027